Compugen (CGEN) to Release Earnings on Monday

Posted by on May 8th, 2023

Compugen (NASDAQ:CGEN – Get Rating) will be releasing its earnings data before the market opens on Monday, May 15th. Analysts expect Compugen to post earnings of ($0.12) per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

Compugen (NASDAQ:CGEN – Get Rating) last posted its earnings results on Monday, February 27th. The biotechnology company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.10. The business had revenue of $7.50 million during the quarter. During the same period last year, the firm posted ($0.10) earnings per share. On average, analysts expect Compugen to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Compugen Stock Performance

Compugen stock opened at $0.63 on Monday. The firm has a market cap of $54.58 million, a price-to-earnings ratio of -1.57 and a beta of 2.71. The stock has a fifty day simple moving average of $0.69 and a two-hundred day simple moving average of $0.82. Compugen has a 12 month low of $0.51 and a 12 month high of $2.36.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on CGEN shares. Jefferies Financial Group downgraded Compugen from a “hold” rating to an “underperform” rating in a research note on Wednesday, February 8th. Oppenheimer restated an “outperform” rating and issued a $8.00 price target on shares of Compugen in a research note on Tuesday, February 28th. SVB Leerink restated an “outperform” rating on shares of Compugen in a research note on Tuesday, February 28th. Finally, StockNews.com started coverage on Compugen in a research note on Thursday, March 16th. They issued a “hold” rating on the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $6.20.

Institutional Investors Weigh In On Compugen

Institutional investors have recently bought and sold shares of the business. Virtu Financial LLC bought a new position in shares of Compugen in the first quarter worth about $37,000. Advisor Group Holdings Inc. grew its holdings in Compugen by 29.3% during the 1st quarter. Advisor Group Holdings Inc. now owns 27,241 shares of the biotechnology company’s stock valued at $87,000 after buying an additional 6,174 shares in the last quarter. Envestnet Asset Management Inc. raised its position in shares of Compugen by 23.4% during the first quarter. Envestnet Asset Management Inc. now owns 33,260 shares of the biotechnology company’s stock valued at $111,000 after buying an additional 6,299 shares during the last quarter. Mariner LLC lifted its holdings in shares of Compugen by 207.3% in the fourth quarter. Mariner LLC now owns 36,831 shares of the biotechnology company’s stock worth $26,000 after buying an additional 24,844 shares in the last quarter. Finally, XTX Topco Ltd lifted its holdings in shares of Compugen by 23.7% in the first quarter. XTX Topco Ltd now owns 44,918 shares of the biotechnology company’s stock worth $145,000 after buying an additional 8,615 shares in the last quarter. Hedge funds and other institutional investors own 25.34% of the company’s stock.

Compugen Company Profile

(Get Rating)

Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses on research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel.

Further Reading

Earnings History for Compugen (NASDAQ:CGEN)

Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.